Inhibitory effect of vitamin C in combination with vitamin K3 on tumor growth and metastasis of Lewis lung carcinoma xenografted in C57BL/6 mice

Nutrition and Cancer

Volumn 63, Issue 7, 2011, Pages 1036-1043

  Chen, Ming Feng ^a,b   Yang, Chih Min ^c   Su, Cheng Ming ^c   Liao, Jiunn Wang ^c   Hu, Miao Lin ^c  

^a SHOW CHWAN MEMORIAL HOSPITAL   (Taiwan)

^b CHINA MEDICAL UNIVERSITY   (Taiwan)

^c NATIONAL CHUNG HSING UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ASCORBIC ACID; CISPLATIN; CYCLINE; GELATINASE A; GELATINASE B; MENADIONE; NUCLEOSIDE DIPHOSPHATE KINASE A; PLASMINOGEN ACTIVATOR INHIBITOR 1; PLASMINOGEN ACTIVATOR INHIBITOR 2; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2; UROKINASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CANCER INVASION; CELL PROLIFERATION; CONTROLLED STUDY; DRUG MEGADOSE; LEWIS CARCINOMA; LOW DRUG DOSE; LUNG METASTASIS; MALE; MOUSE; NONHUMAN; ORGAN WEIGHT; PROTEIN EXPRESSION; TUMOR GROWTH; TUMOR XENOGRAFT;

ANIMALS; ASCORBIC ACID; BLOTTING, WESTERN; CARCINOMA, LEWIS LUNG; CELL LINE; CELL LINE, TUMOR; CELL PROLIFERATION; CISPLATIN; DOSE-RESPONSE RELATIONSHIP, DRUG; LUNG NEOPLASMS; MALE; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MICE; MICE, INBRED C57BL; NEOPLASM INVASIVENESS; PLASMINOGEN ACTIVATOR INHIBITOR 1; TISSUE INHIBITOR OF METALLOPROTEINASE-1; TISSUE INHIBITOR OF METALLOPROTEINASE-2; TRANSPLANTATION, HETEROLOGOUS; UROKINASE-TYPE PLASMINOGEN ACTIVATOR; VITAMIN K 3;

MUS;

EID: 80053646699     PISSN: 01635581     EISSN: 15327914     Source Type: Journal    
DOI: 10.1080/01635581.2011.597537     Document Type: Article

References (40)

1. Weiss L: Metastatic inefficiency. Adv Cancer Res 54, 159-211, 1990. (Pubitemid 20088338)
2. Mehlen P and Puisieux A: Metastasis: a question of life or death. Nat Rev Cancer 6, 449-458, 2006.
3. Levine M, Rumsey SC, Daruwala R, Park JB, and Wang Y: Criteria and recommendations for vitamin C intake. JAMA 281, 1415-1423, 1999. (Pubitemid 29190220)
4. Yeom CH, Lee G, Park JH, Yu J, Park S et al.: High dose concentration administration of ascorbic acid inhibits tumor growth in BALB/C mice implanted with sarcoma 180 cancer cells via the restriction of angiogenesis. J Transl Med 7, 70, 2009.
5. Belin S, Kaya F, Duisit G, Giacometti S, Ciccolini J, et al.: Antiproliferative effect of ascorbic acid is associated with the inhibition of genes necessary to cell cycle progression. PLoS One 4, e4409, 2009.
6. Ogasawara M, Matsunaga T, and Suzuki H: Differential effects of antioxi-dants on the in vitro invasion, growth and lung metastasis of murine colon cancer cells. Biol Pharm Bull 30, 200-204, 2007. (Pubitemid 46066348)
7. Pollard HB, Levine MA, Eidelman O, and Pollard M: Pharmacological ascorbic acid suppresses syngeneic tumor growth and metastases in hormone-refractory prostate cancer. In Vivo 24, 249-255, 2010.
8. Handel J and Tripp JH: Vitamin K prophylaxis against haemorrhagic disease of the newborn in the United Kingdom. Br Med J 303, 1109, 1991.
9. Verrax J, Cadrobbi J, Delvaux M, Jamison JM, Gilloteaux J, et al.: The association of vitamins C and K3 kills cancer cells mainly by autoschizis, a novel form of cell death. Basis for their potential use as coadjuvants in anticancer therapy. Eur J Med Chem 38, 451-457, 2003. (Pubitemid 36588911)
10. Chlebowski RT, Dietrich M, Akman S, and Block JB: Vitamin K3 inhibition of malignant murine cell growth and human tumor colony formation. Cancer Treat Rep 69, 527-532, 1985. (Pubitemid 15031402)
11. Nishikawa Y, Carr BI, Wang M, Kar S, Finn F, et al.: Growth inhibition of hepatoma cells induced by vitamin K and its analogs. J Biol Chem 270, 28304-28310, 1995.
12. Bouzahzah B, Nishikawa Y, Simon D, and Carr BI: Growth control and gene expression in a new hepatocellular carcinoma cell line, Hep40: inhibitory actions of vitamin K. J Cell Physiol 165, 459-467, 1995. (Pubitemid 26004303)
13. Maeda M, Murakami M, Takegami T, and Ota T: Promotion or suppression of experimental metastasis of B16 melanoma cells after oral administration of lapachol. Toxicol Appl Pharmacol 229, 232-238, 2008.
14. Akiyoshi T, Matzno S, Sakai M, Okamura N, and Matsuyama K: The potential of vitamin K3 as an anticancer agent against breast cancer that acts via the mitochondria-related apoptotic pathway. Cancer Chemother Pharmacol 65, 143-150, 2009.
15. Chiou TJ, Chu ST, and Tzeng WF: Protection of cells from menadione-induced apoptosis by inhibition of lipid peroxidation. Toxicology 191, 77-88, 2003.
16. Venugopal M, Jamison JM, Gilloteaux J, Koch JA, Summers M, et al.: Synergistic antitumour activity of vitamins C and K3 against human prostate carcinoma cell lines. Cell Biol Int 20, 787-797, 1996. (Pubitemid 27075506)
17. Venugopal M, Jamison JM, Gilloteaux J, Koch JA, Summers M, et al.: Synergistic antitumor activity of vitamins C and K3 on human urologic tumor cell lines. Life Sci 59, 1389-1400, 1996. (Pubitemid 26344373)
18. Gilloteaux J, Jamison JM, Arnold D, Neal DR, and Summers JL: Morphology and DNA degeneration during autoschizic cell death in bladder carcinoma T24 cells induced by ascorbate and menadione treatment. Anat Rec A Discov Mol Cell Evol Biol 288, 58-83, 2006. (Pubitemid 43062594)
19. Taper HS, Jamison JM, Gilloteaux J, Gwin CA, Gordon T, et al.: In vivo reactivation of DNases in implanted human prostate tumors after administration of a vitamin C/K(3) combination. J Histochem Cytochem 49, 109-120, 2001.
20. Taper HS, Jamison JM, Gilloteaux J, Summers JL, and Calderon PB: Inhibition of the developmentof metastasesby dietary vitamin C:K3 combination. Life Sci 75, 955-967, 2004. (Pubitemid 38749255)
21. Beck R, Pedrosa RC, Dejeans N, Glorieux C, Leveque P, et al.: Ascorbate/menadione-induced oxidative stress kills cancer cells that express normalor mutated forms of the oncogenic protein Bcr-Abl. An in vitro and in vivo mechanistic study. Invest New Drugs. doi: 10.1007/s10637-010-9441-3, 2010.
22. Parkin DM: Global cancer statistics in the year 2000. Lancet Oncol 2, 533-543, 2001. (Pubitemid 33586866)
23. Kleiner DE and Stetler-Stevenson WG: Quantitative zymography: detection of picogram quantities of gelatinases. Anal Biochem 218, 325-329, 1994. (Pubitemid 24141631)
24. Ramos-Vara JA: Technical aspects of immunohistochemistry. Vet Pathol 42, 405-426, 2005. (Pubitemid 40993852)
25. Taper HS, de Gerlache J, Lans M, and Roberfroid M: Non-toxic potentiation of cancer chemotherapy by combined C and K3 vitamin pre-treatment. Int J Cancer 40, 575-579, 1987. (Pubitemid 17148749)
26. Duffy MJ and McCarthy K: Matrix metalloproteinases in cancer: prognostic markers and targets for therapy (review). Int J Oncol 12, 1343-1348, 1998. (Pubitemid 28239947)
27. Itoh T, Tanioka M, Yoshida H, Yoshioka T, Nishimoto H, et al.: Reduced angiogenesis and tumor progression in gelatinase A-deficient mice. Cancer Res 58, 1048-1051, 1998. (Pubitemid 28182477)
28. Kong D, Li Y, Wang Z, Banerjee S, and Sarkar FH: Inhibition of angio-genesis and invasion by 3, 3'-diindolylmethane is mediated by the nuclear factor-kappaB downstream target genes MMP-9 and uPA that regulated bioavailability of vascular endothelial growth factor in prostate cancer. Cancer Res 67, 3310-3319, 2007. (Pubitemid 46724870)
29. Nagase H: Activation mechanisms of matrix metalloproteinases. Biol Chem 378, 151-160, 1997. (Pubitemid 27230597)
30. Watanabe M, Takahashi Y, Ohta T, Mai M, Sasaki T, et al.: Inhibition of metastasis in human gastric cancer cells transfected with tissue inhibitor of metalloproteinase 1 gene in nude mice. Cancer 77(8 Suppl), 1676-1680, 1996. (Pubitemid 26111851)
31. Iwata H, Kobayashi S, Iwase H, and Okada Y: The expression of MMPs and TIMPs in human breast cancer tissues and importance of their balance in cancer invasion and metastasis. Nippon Rinsho 53, 1805-1810, 1995.
32. Kawamata H, Kawai K, Kameyama S, Johnson MD, Stetler-Stevenson WG, et al.: Overexpression of tissue inhibitor of matrix metalloproteinases (TIMP1 and TIMP2) suppresses extravasation of pulmonary metastasis of a rat bladder carcinoma. Int J Cancer, 63, 680-687, 1995.
33. Steeg PS, Bevilacqua G, Pozzatti R, Liotta LA, and Sobel ME: Altered expression of NM23, a gene associated with low tumor metastatic potential, during adenovirus 2 Ela inhibition of experimental metastasis. Cancer Res 48, 6550-6554, 1988.
34. Onisto M, Garbisa S, Caenazzo C, Freda MP, Di Francesco C, et al.: Reverse transcription-polymerase chain reaction phenotyping of metalloproteinases and inhibitors involved in tumor matrix invasion. Diagn Mol Pathol 2, 74-80, 1993. (Pubitemid 23236008)
35. Mackay AR, Corbitt RH, Hartzler JL, and Thorgeirsson UP: Basement membrane type IV collagen degradation: evidence for the involvement of a proteolytic cascade independent of metalloproteinases. Cancer Res 50, 5997-6001, 1990. (Pubitemid 20331412)
36. Laskey RA, Fairman MP, and Blow JJ: S phase of the cell cycle. Science 246, 609-614, 1989. (Pubitemid 19283351)
37. Galand P and Degraef C: Cyclin/PCNA immunostaining as an alternative to tritiated thymidine pulse labelling for marking S phase cells in paraffin sections from animal and human tissues. Cell Tissue Kinet 22, 383-392, 1989. (Pubitemid 20069478)
38. Hall PA, Levison DA, Woods AL, Yu CC, Kellock DB, et al.: Proliferating cell nuclear antigen (PCNA) immunolocalization in paraffin sections: an index of cell proliferation with evidence of deregulated expression in some neoplasms. J Pathol 162, 285-294, 1990.
39. Pelosi G, Zamboni G, Doglioni C, Rodella S, Bresaola E, et al.: Immun-odetection of proliferating cell nuclear antigen assesses the growth fraction and predicts malignancy in endocrine tumors of the pancreas. Am J Surg Pathol 16, 1215-1225, 1992. (Pubitemid 23004427)
40. U.S. Food and Drug Administration, Department of Health and Human Services: Objectivity in research. Federal Register 60, 35809-35819, 1995.